Singapore, Aug. 12 -- China-based Fosun Pharma has signed a license agreement with Expedition Therapeutics Inc.to grant the rights to develop, manufacture, and commercialise XH-S004, an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor independently developed by Fosun Pharma, in all regions globally except Chinese Mainland, Hong Kong SAR and Macau SAR.
Fosun Pharma will retain the rights to develop, manufacture, and commercialise XH-S004 in Chinese Mainland, Hong Kong SAR and Macau SAR.
Under the agreement, Expedition will pay Fosun Pharma up to $120 million including upfront payment and development milestone payments. In addition, based on the annual net sales of XH-004 in the licensed territories, Expedition will pay up to ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.